Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 2
2006 3
2007 1
2008 2
2009 4
2010 1
2011 2
2012 1
2013 3
2014 2
2015 6
2016 7
2017 6
2018 3
2019 1
2020 5
2021 7
2022 8
2023 10
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

64 results

Results by year

Filters applied: . Clear all
Page 1
IL-2-driven CD8+ T cell phenotypes: implications for immunotherapy.
Niederlova V, Tsyklauri O, Kovar M, Stepanek O. Niederlova V, et al. Among authors: kovar m. Trends Immunol. 2023 Nov;44(11):890-901. doi: 10.1016/j.it.2023.09.003. Epub 2023 Oct 10. Trends Immunol. 2023. PMID: 37827864 Free PMC article. Review.
Tertiary lymphoid structures and B cells determine clinically relevant T cell phenotypes in ovarian cancer.
Kasikova L, Rakova J, Hensler M, Lanickova T, Tomankova J, Pasulka J, Drozenova J, Mojzisova K, Fialova A, Vosahlikova S, Laco J, Ryska A, Dundr P, Kocian R, Brtnicky T, Skapa P, Capkova L, Kovar M, Prochazka J, Praznovec I, Koblizek V, Taskova A, Tanaka H, Lischke R, Mendez FC, Vachtenheim J Jr, Heinzelmann-Schwarz V, Jacob F, McNeish IA, Halaska MJ, Rob L, Cibula D, Orsulic S, Galluzzi L, Spisek R, Fucikova J. Kasikova L, et al. Among authors: kovar m. Nat Commun. 2024 Mar 21;15(1):2528. doi: 10.1038/s41467-024-46873-w. Nat Commun. 2024. PMID: 38514660 Free PMC article.
Type I interferon signaling in malignant blasts contributes to treatment efficacy in AML patients.
Holicek P, Truxova I, Rakova J, Salek C, Hensler M, Kovar M, Reinis M, Mikyskova R, Pasulka J, Vosahlikova S, Remesova H, Valentova I, Lysak D, Holubova M, Kaspar P, Prochazka J, Kasikova L, Spisek R, Galluzzi L, Fucikova J. Holicek P, et al. Among authors: kovar m. Cell Death Dis. 2023 Mar 24;14(3):209. doi: 10.1038/s41419-023-05728-w. Cell Death Dis. 2023. PMID: 36964168 Free PMC article.
Engineered cytokine/antibody fusion proteins improve delivery of IL-2 to pro-inflammatory cells and promote antitumor activity.
Leonard EK, Tomala J, Gould JR, Leff MI, Lin JX, Li P, Porter MJ, Johansen ER, Thompson L, Cao SD, Henclova T, Huliciak M, Vaněk O, Kovar M, Leonard WJ, Spangler JB. Leonard EK, et al. Among authors: kovar m. bioRxiv [Preprint]. 2023 May 4:2023.05.03.539272. doi: 10.1101/2023.05.03.539272. bioRxiv. 2023. PMID: 37205604 Free PMC article. Preprint.
Novel IL-2-Poly(HPMA)Nanoconjugate Based Immunotherapy.
Votavova P, Tomala J, Subr V, Strohalm J, Ulbrich K, Rihova B, Kovar M. Votavova P, et al. Among authors: kovar m. J Biomed Nanotechnol. 2015 Sep;11(9):1662-73. doi: 10.1166/jbn.2015.2114. J Biomed Nanotechnol. 2015. PMID: 26485935
64 results